By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Universal Times MagazineUniversal Times MagazineUniversal Times Magazine
  • Home
  • Industries
    • Automobile
    • Aviation
    • Banking
    • Cryptocurrency
    • E- Commerce
    • EdTech
    • Energy and Petroleum
    • Fintech
    • FMCG
    • Information Technology
    • NBFC
    • Oil
    • Pharmacy
    • Telecom
    • Other Business News
  • Blogs
  • World
  • Jobs
  • Careers
  • About us
  • Privacy Policy
  • Contact
Search
Copyright © 2020-2024 Universal Times Magazine. All Rights Reserved.
Reading: Divi’s Labs enter the elite club of Rs 1 trillion Market Cap
Share
Notification
Aa
Universal Times MagazineUniversal Times Magazine
Aa
  • Home
  • Industries
  • Blogs
  • World
  • Jobs
  • Careers
  • About us
  • Privacy Policy
  • Contact
Search
  • Home
  • Industries
    • Automobile
    • Aviation
    • Banking
    • Cryptocurrency
    • E- Commerce
    • EdTech
    • Energy and Petroleum
    • Fintech
    • FMCG
    • Information Technology
    • NBFC
    • Oil
    • Pharmacy
    • Telecom
    • Other Business News
  • Blogs
  • World
  • Jobs
  • Careers
  • About us
  • Privacy Policy
  • Contact
Follow US
  • Home
  • Industries
  • Blogs
  • World
  • Jobs
  • Careers
  • About us
  • Privacy Policy
  • Contact
Copyright © 2020-2024 Universal Times Magazine. All Rights Reserved.

Advertisement

Universal Times Magazine > Blog > Pharmacy > Divi’s Labs enter the elite club of Rs 1 trillion Market Cap
Pharmacy

Divi’s Labs enter the elite club of Rs 1 trillion Market Cap

Gaurav Verma
Last updated: 2020/12/17 at 12:42 PM
Gaurav Verma
Share
3 Min Read
SHARE

Advertisement

Divi’s Laboratories entered the elite club of companies with a market capitalisation (market-cap) of Rs 1 trillion.

Contents
About CompanyCompany’s Financial2nd firm in his sector to cross the milestoneComment from broking firm ShareKhanStock Market

The move came after the firm’s stock price hit a new high of Rs 3,832, up 3 per cent, on Thursday. 

Investors have been buying into Divi’s Labs on strong earnings visibility from its aggressive capax plan.

The company has been witnessing strong demand for both active pharmaceutical ingredients (API) and custom synthesis operations.

About Company

Divi’s Laboratories, one of the world’s largest generic active pharmaceutical ingredient manufacturers, is also the best performer on the Nifty 50 so far this year, gaining more than 100%.

It’s the only Nifty 50 constituent to have witnessed a twofold jump in its stock price this year as the benchmarks rebounded to scale new peaks.

Company’s Financial

For the September quarter, the company’s revenue grew 21% year-on-year to ₹1,750 crore.

Generic sales rose 23% while costom synthesis sales advanced 18%.

Gross margins expanded 820 basis points while profit increased 47% to ₹530 crore.

- Advertisement -
Ad image

2nd firm in his sector to cross the milestone

It is the second most valued pharma company enter the elite club after Sun Pharmaceutical Industries, which has market-cap of Rs 1.40 trillion.

Divis Labs stands at the 30th position among Indian companies having market-cap of over Rs 1 trillion (including all sectors).

Comment from broking firm ShareKhan

“We expect Divi’s to reap benefits of backward integration, capacity expansion, and emerging opportunities in the API and custom synthesis space.

Strong earnings visibility, almost zero debt, and strong return ratios bode well from a growth perspective. Moreover, the company does not have any pending regulatory hurdles, which is a key positive.”

Stock Market

The stock opened at Rs 3,719 on BSE against the previous close of Rs 3,719.45 and touched a high of Rs 3,847.90 in the trade so far.

The pharma sector has been among the top beneficiaries of the COVID-19 pandemic and the stock of Divi’s has been among the top performers of the pharma pack.

Press the Bell Icon for notifications of all updates

Advertisement

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
[mc4wp_form]
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Gaurav Verma December 17, 2020 December 17, 2020
Share This Article
Facebook Twitter Whatsapp Whatsapp LinkedIn Copy Link
Share
Avatar
By Gaurav Verma
Follow:
Founder
Previous Article Facebook criticises Apple privacy policy over Mobile devices
Next Article L & T Hiring for Chartered Accountant-Corporate Accounts

Stay Connected

2.2k Followers Like
727 Followers Follow
25.7k Followers Follow
444 Subscribers Subscribe

Advertisement

Advertisement

Latest News

Advertisement

Advertisement

Follow US
Copyright © 2020-2025 Universal Times Magazine. All Rights Reserved.
adbanner
AdBlock Detected
Our site is an advertising supported site. Please whitelist to support our site.
Okay, I'll Whitelist
Welcome Back!

Sign in to your account

Lost your password?

Subscribe For Latest Updates

Sign up to best of business news, informed analysis and opinions on what matters to you.

Invalid email address
We promise not to spam you. You can unsubscribe at any time.
Thanks for subscribing!